Clinical research organization Veristat has a new leader as the Southborough-based firm promoted Kim McLean Boericke to the role of CEO.
Boericke most recently served as Veristat’s COO, and in her new capacities, will work to grow the company’s therapeutic specializations in oncology, neurology, and rare diseases, according to a Jan. 13 press release from Veristat.
Boericke succeeds Patrick Flanagan, who served as Veristat’s CEO for 13 years. During his tenure, Flanagan helped advance over 180 regulatory application submissions, leading to 120 approved therapies. While stepping down from his leading role, Flanagan will stay with Veristat as a member of its board of directors.
“Veristat is unique in that it was built on a strong foundation of scientific integrity, a client focus, and high-quality clinical trial support. Kim’s expertise, combined with her strategic and efficient approach to implementing solutions, will advance Veristat as the company continues to innovate and grow in supporting our clients’ most complex clinical trials and the patients they serve,” Flanagan said in the release.
Prior to joining Veristat in 2024, Boericke held leadership roles at biotech research firms for more than 20 years. She previously served as COO of THREAD, a clinical research firm out of North Carolina; as president of commercialization and outcomes at ICON plc, a Dublin-based clinical research organization; and as vice president and managing director of IQVIA, a clinical research services provider out of North Carolina, according to her LinkedIn profile.
“Veristat is at the forefront of clinical research, and I’m excited to continue building on our company’s vision to help bring the most advanced therapies to patients,” Boericke said in the release. “My immediate focus will be on expanding Veristat’s early-stage strategic consulting capabilities, enabling closer collaboration with clients to finalize and deliver drug development programs, optimize clinical trial design, and streamline regulatory pathways to approval.”
Boericke graduated with her bachelor’s degree from Duke University in North Carolina, according to her LinkedIn profile.
Founded in 1994, Veristat is contracted by biotech companies to support their clinical testing and drug development to produce novel therapies in areas including oncology, neurology, and infectious disease.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries.
